Cannabinoid Delivery Systems for Pain and Inflammation Treatment Natascia Bruni, Carlo Della Pepa, Simonetta Oliaro-Bosso, Enrica Pessione, Daniela Gastaldi and Franco Dosio Molecules, 2018, 23, 2478 doi:10.3390/molecules23102478 www.mdpi.com/journal/molecules Abstract : There is a growing body of evidence to suggest that cannabinoids are beneficial for a range of clinical conditions, including pain, inflammation, epilepsy, sleep disorders, the symptoms of multiple sclerosis, anorexia, schizophrenia and other conditions. The transformation of cannabinoids from herbal preparations into highly regulated prescription drugs is therefore progressing rapidly. The development of such drugs requires well-controlled clinical trials to be carried out in order to objectively establish therapeutic efficacy, dose ranges and [...]
Lire la suiteCannabis and Pain: A Clinical Review Kevin P. Hill, Matthew D. Palastro, Brian Johnson, and Joseph W. Ditre Cannabis and Cannabinoid Research, Volume 2.1, 2017 DOI: 10.1089/can.2017.0017 Abstract Introduction: Cannabis has been used for medical purposes across the world for centuries. As states and countries implement medical and recreational cannabis policies, increasing numbers of people are using cannabis pharmacotherapy for pain. There is a theoretical rationale for cannabis' efficacy for pain management, although the subjective pain relief from cannabis may not match objective measurements of analgesia. As more patients turn to cannabis for pain relief, there is a need for additional scientific evidence to evaluate [...]
Lire la suiteCANNABIS ET CANNABIDIOL : Éléments de Compréhension Dr Sarah Lejczak La Lettre du RESPADD, 35, avril 2019 Depuis 5000 ans, le cannabis ruderalids, sativa ou indica est utilisé dans la pharmacopée humaine de manière informelle pour ses différentes propriétés antihémétiques, antiépileptiques, antispastiques, antalgiques, anxiolytiques, antihypertensives, etc. (1). Suite à son introduction dans l’arsenal pharmaceutique moderne au XIXème siècle et les dérives d’utilisation récréative au cours du XXème siècle, son utilisation a été interdite et reste très controversée de nos jours. Des extraits cannabinoïdes (2) (Delta-9-tetrahydrocannabinol (Δ-9-THC), cannabidiol (CBD) et cannabinol (CBN) majoritairement) de la plante ou fabriqués synthétiquement sont utilisés depuis 1985 en tant que médicaments. [...]
Lire la suiteOvercoming the Bell‐Shaped Dose‐Response of Cannabidiol by Using Cannabis Extract Enriched in Cannabidiol Ruth Gallily, Zhannah Yekhtin, Lumír Ondřej Hanuš Pharmacology & Pharmacy, 2015, 6, 75-85 http://dx.doi.org/10.4236/pp.2015.62010 Abstract : Cannabidiol (CBD), a major constituent of Cannabis, has been shown to be a powerful anti inflammatory and anti‐anxiety drug, without exerting a psychotropic effect. However, when given either intraperitoneally or orally as a purified product, a bell‐shaped dose‐response was observed, which limits its clinical use. In the present study, we have studied in mice the anti‐inflammatory and anti nociceptive activities of standardized plant extracts derived from the Cannabis sativa L., clone 202, which is highly enriched [...]
Lire la suiteA Cross-Sectional Survey of Medical Cannabis Users : Patterns of Use and Perceived Efficacy Michelle Sexton, Carrie Cuttler, John S. Finnell, and Laurie K. Mischley Cannabis and Cannabinoid Research, 2016, Volume 1.1, 131-138 DOI: 10.1089/can.2016.0007 Abstract Background: The political climate around Cannabis as a medicine is rapidly changing. Legislators are adopting policies regarding appropriate medical applications, while the paucity of research may make policy decisions around conditions for which Cannabis is an effective medicine difficult. Methods: An anonymous online survey was developed to query medical Cannabis users about the conditions they use Cannabis to treat, their use patterns, perception of efficacy, and physical and mental health. [...]
Lire la suiteCannabinoid Actions on Neural Stem Cells : Implications for Pathophysiology Rui S. Rodrigues, Diogo M. Lourenço, Sara L. Paulo, Joana M. Mateus, Miguel F. Ferreira, Francisco M. Mouro, João B. Moreira, Filipa F. Ribeiro, Ana M. Sebastião and Sara Xapelli Molecules, 2019, 24, 1350, 59 pp. Abstract : With the increase of life expectancy, neurodegenerative disorders are becoming not only a health but also a social burden worldwide. However, due to the multitude of pathophysiological disease states, current treatments fail to meet the desired outcomes. Therefore, there is a need for new therapeutic strategies focusing on more integrated, personalized and effective approaches. The prospect [...]
Lire la suiteModulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid. Ewa Kozela, Ana Juknat, and Zvi Vogel International Journal of Molecular Sciences, 2017, 18, 1669, 20 pp. doi:10.3390/ijms18081669 PMID : 28788104 PMCID : PMC5578059 Abstract The astrocytes have gained in recent decades an enormous interest as a potential target for neurotherapies, due to their essential and pleiotropic roles in brain physiology and pathology. Their precise regulation is still far from understood, although several candidate molecules/systems arise as promising targets for astrocyte-mediated neuroregulation and/or neuroprotection. The cannabinoid system and its ligands have been shown to interact and affect activities of astrocytes. Cannabidiol (CBD) is the main [...]
Lire la suiteCannabinoid signalling in the immature brain: Encephalopathies and neurodevelopmental disorders Onintza Sagredo, Javier Palazuelos, Ana Gutierrez-Rodriguez, Valentina Satta, Ismael Galve-Roperh, Jose Martinez-Orgado Biochemical Pharmacology, 2018, 157, 85-96 DOI : 10.1016/j.bcp.2018.08.014 Abstract The endocannabinoid system exerts a crucial neuromodulatory role in many brain areas that is essential for proper regulation of neuronal activity. The role of cannabinoid signalling controlling neuronal activity in the adult brain is also evident when considering its contribution to adult brain insults or neurodegenerative diseases. In the context of brain genetic or acquired encephalopathies administration of cannabinoid-based molecules has demonstrated to exert symptomatic relief and hence, they are proposed as new potential [...]
Lire la suiteCannabinoïd-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System Patricia Schonhofen, Ivi Juliana Bristot, Jose Alexandre Crippa et al. CNS Drugs, 2018, 32(Suppl 1), 1-16 DOI : 10.1007/s40263-018-0550-4 Abstract The endocannabinoid retrograde signaling pathway is widely expressed in the central nervous system, where it plays major roles in regulating synaptic plasticity (excitatory and inhibitory) through long-term potentiation and long-term depression. The endocannabinoid system (ECS) components—cannabinoid receptors, endocannabinoids and synthesis/degradation enzymes—are expressed and are functional from early developmental stages and throughout adolescent cortical development, regulating progenitor cell fate, neural differentiation, migration and survival. This may potentially confer increased vulnerability to [...]
Lire la suiteCannabis, Cannabidiol, and Epilepsy. Clinical Considerations and Practical Applications A new frontier brings new questions and old dilemmas. Adrian L. Turner and M. Scott Perry Practical Neurology, October 2018, 31-35 Background As early as 12,000 BCE, texts from central Asia reported human use of cannabis for nonmedical indications including ropes, fibers, and cloth. Ancient Chinese manuscripts from approximately 10,000 years later give the first documented use of cannabis for medical purposes 1. Other early reports from ancient Mesopotamia, Persia, and India describe cannabis use for indications such as spasticity, depression, anxiety, and epilepsy.1,2 Cannabis for medicinal purposes was not scientifically studied until the 19th century. In 1840, William [...]
Lire la suite